Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 04 Jun 2025
At a glance
- Drugs ORIN 1001 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Fosun Orinove
Most Recent Events
- 30 May 2025 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.
- 30 May 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2025.
- 31 Dec 2024 Status changed from active, no longer recruiting to suspended due to partnership activities ongoing